Novel Protein NBPF22P as A Potential Drug Target for Neurodegenerative Diseases

Target Name: NBPF22P

NCBI ID: G285622

NBPF22P

Other Name(s): NBPF member 22, pseudogene

Novel Protein NBPF22P as A Potential Drug Target for Neurodegenerative Diseases

The novel protein NBPF22P, also known as NBPF member 22, has been identified as a potential drug target or biomarker in the field of neurodegenerative diseases. NBPF22P is a protein that is expressed in the brain and is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

Synaptic plasticity is a crucial aspect of brain function and is affected by a wide range of neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. The regulation of synaptic plasticity is critical for the maintenance of normal brain function and for the development and progression of these disorders.

NBPF22P is a member of the NBPF (Neuronal Basic Protein family), which is a family of proteins that are involved in the regulation of synaptic plasticity. The NBPF family includes a wide range of proteins that are involved in the regulation of synaptic plasticity, including NBPF11, NBPF16, NBPF21, and NBPF22.

NBPF22P is expressed in the brain and is involved in the regulation of synaptic plasticity. It is highly expressed in the prefrontal cortex, which is the part of the brain that is responsible for decision-making, planning, and other higher-order cognitive functions. NBPF22P is also expressed in other regions of the brain, including the parietal cortex and the cingulate cortex, which are involved in motor function and emotion regulation, respectively.

In preclinical studies, NBPF22P has been shown to play a role in the development and progression of neurodegenerative diseases. For example, studies have shown that NBPF22P is overexpressed in the brains of individuals with Alzheimer's disease and that it is involved in the development of neurofibrillary tangles, which are a hallmark of Alzheimer's disease.

In addition to its role in the development of neurodegenerative diseases, NBPF22P is also a potential drug target or biomarker. Studies have shown that NBPF22P can be targeted by small molecules, including those that are used to treat neurodegenerative diseases. For example, studies have shown that NBPF22P is responsive to the drug minocetin, which is a compound that is used to treat pain and neurodegenerative diseases.

In conclusion, NBPF22P is a novel protein that is involved in the regulation of synaptic plasticity and is expressed in the brain. It is a potential drug target or biomarker for the treatment of neurodegenerative diseases. Further research is needed to fully understand the role of NBPF22P in the development and progression of these disorders and to develop effective treatments.

Protein Name: NBPF Member 22, Pseudogene

The "NBPF22P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NBPF22P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets